Regulatory

Ascelia Pharma publishes Annual Report for the financial year 2018/2019

2019-10-14
Download

Ascelia Pharma’s Annual Report for the financial year 2018/2019 has today been published on the company’s website www.ascelia.com

For further information, please contact:
Mikael Widell, Head of IR & Communications
Email: mw@ascelia.com
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 6.00 p.m. CET on 14 October 2019.

2020-10-21

Upgraded estimate of addressable market for Mangoral to $500-600 million annually

Ascelia Pharma AB (publ) (ticker: ACE) today announced that its estimate of the addressable market in the US, EU and Japan for its lead candidate drug Mangoral has been increased to $500-600 million (previously $350-500 million). Preparations for launch are progressing well, with a strong case for own commercialization in the US. Investors, analysts and media are invited to today’s virtual Capital Markets Day where Mangoral’s market opportuni ...
2020-09-30

Invitation to Ascelia Pharma’s virtual Capital Markets Day

Ascelia Pharma AB (publ) (ticker: ACE) hereby invites analysts, investors and media to its virtual Capital Markets Day on Wednesday October 21, 2020. Focus of the day will be on Mangoral market opportunity and preparations for commercialization.
2020-09-18

First commercial scale manufacturing of Mangoral

Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) today announced that the company has reached a key achievement with the first commercial scale manufacturing of its lead compound Mangoral, currently in pivotal Phase 3 development. The commercial scale manufacturing is an important step towards market launch.